U.S. Markets close in 2 hrs 15 mins
  • S&P 500

    4,572.90
    +40.14 (+0.89%)
     
  • Dow 30

    35,298.10
    +269.45 (+0.77%)
     
  • Nasdaq

    14,545.00
    +204.75 (+1.43%)
     
  • Russell 2000

    2,083.13
    +20.35 (+0.99%)
     
  • Crude Oil

    86.91
    -0.05 (-0.06%)
     
  • Gold

    1,847.80
    +4.60 (+0.25%)
     
  • Silver

    24.61
    +0.38 (+1.58%)
     
  • EUR/USD

    1.1334
    -0.0013 (-0.1133%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • Vix

    22.17
    -1.68 (-7.04%)
     
  • GBP/USD

    1.3636
    +0.0025 (+0.1800%)
     
  • USD/JPY

    114.1120
    -0.2410 (-0.2107%)
     
  • BTC-USD

    43,013.82
    +1,028.83 (+2.45%)
     
  • CMC Crypto 200

    1,027.47
    +32.20 (+3.24%)
     
  • FTSE 100

    7,558.65
    -31.01 (-0.41%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 22, 2021.

A live webcast and archive of the fireside chat will be available online from the investor relations section of the company website at www.progenity.com.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information about Progenity’s products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436